Mavrilimumab 30 mg ( DrugBank: Mavrilimumab )

1 disease
IDDisease name (Link within this page)Number of trials
46Malignant rheumatoid arthritis2

46. Malignant rheumatoid arthritis

Clinical trials : 4,356 /  Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01706926
(ClinicalTrials.gov)		August 20123/10/2012A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid ArthritisA Phase 2b Study to Evaluate the Efficacy and Safety of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid ArthritisRheumatoid ArthritisBiological: Mavrilimumab 30 mg;Biological: Mavrilimumab 100 mg;Biological: Mavrilimumab 150 mg;Other: PlaceboMedImmune LLCMedImmune LtdCompleted18 Years80 YearsAll420Phase 2Argentina;Bulgaria;Chile;Colombia;Czech Republic;Estonia;Germany;Hungary;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;France;Mexico
2NCT01050998
(ClinicalTrials.gov)		January 5, 201015/1/2010A Study to Evaluate the Efficacy and Safety of CAM-3001 (Drug) in Subjects With Rheumatoid ArthritisA Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Efficacy and Safety of CAM-3001 in Subjects With Rheumatoid ArthritisRheumatoid ArthritisBiological: Mavrilimumab 10 mg;Biological: Mavrilimumab 30 mg;Biological: Mavrilimumab 50 mg;Biological: Mavrilimumab 100 mg;Other: PlaceboMedImmune LLCMedImmune LtdCompleted18 Years80 YearsAll516Phase 2Bulgaria;Czechia;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;Czech Republic;Serbia